We are excited to announce that Exactics has successfully raised $15,000 in new funding, marking a significant milestone for our rapidly growing, UChicago/Tulane undergrad-founded startup. At Exactics, we are dedicated to developing rapid, reliable, and cost-effective diagnostic technologies for infectious diseases, and this infusion of capital underscores the confidence investors have in our innovative approach. Our flagship product, QuickLyme®, is a lab-free rapid test that detects Lyme disease in ticks within just 15 minutes, enabling individuals, whether pet owners or concerned community members, to make swift, informed decisions regarding treatment after a tick bite. Beyond QuickLyme®, we are proud to hold multiple patents for our novel diagnostic platform, Proteus+™, which has the transformative potential to be tailored for over 200 arthropod-borne diseases.
This new funding will be instrumental in accelerating our ongoing research and expanding the capabilities of the Proteus+™ platform to include diagnostics for diseases such as malaria, dengue fever, Lassa fever, and West Nile virus, among others. With collaborative research initiatives underway with institutions in Illinois and Nigeria, we intend to further refine our technology to combat neglected tropical diseases effectively. Our founding team of five undergraduates—supported by an esteemed board of advisors from institutions including Harvard Medical School and the University of Cambridge—continues to drive innovations through partnerships like the NSF i-Corps program and the Polsky BUILD Accelerator. This funding not only fuels our research and development goals but also propels our mission to deliver affordable and accessible diagnostics worldwide. For more information or inquiries, please contact us at contact@exacticsbiotech.com.
